BSIM Therapeutics results published in Amyloid, The Journal
25 July, 2019
Results published in Amyloid, The Journal, show that one of the technologies developed by BSIM Therapeutics stabilizes transthyretin in the cerebrospinal fluid and in the vitreous humor.
By continuing to browse the site, you expressly agree that cookies will be stored on your computer to help measure statistics of visits and improve the quality of the contents offered.Learn more